About this Research Topic
Despite the notable advancements in cancer pharmacotherapy, such as chemotherapy, targeted therapy, and immunotherapy, which have significantly improved patient survival rates, managing the associated adverse reactions remains a major clinical challenge. These reactions encompass a wide array of effects, both typical and atypical, including drug resistance, impairments in normal physiological functions, treatment-induced pain, and gastrointestinal issues. Adverse drug reactions (ADRs) pose a serious threat to patient health, severely limiting the effectiveness and safety of anti-cancer therapies. Cancer patients, compared to those with other diseases, are at a higher risk of ADRs, which often lead to rare but severe effects, profoundly impacting their quality of life. Therefore, assessing and controlling adverse drug reactions is crucial and must be explored and addressed in the development of cancer treatments.
Pharmacovigilance is central in this regard, focusing on the detection, evaluation, understanding, and prevention of adverse reactions and other drug-related issues. This discipline includes the early identification of unknown adverse drug reactions and their interactions, monitoring the trends in known reactions, analyzing the risk factors and potential mechanisms, and conducting quantitative risk-benefit assessments. Meanwhile, pharmacoepidemiology applies epidemiological methods and principles to study the use and effects of drugs in specific populations. Through descriptive, analytical (including case-control and cohort studies), and experimental studies (such as randomized controlled trials and community trials), it provides valuable insights and recommendations for rational drug use, thereby making drug development, production, management, and utilization more rational.
Insights gained from pharmacovigilance and pharmacoepidemiology offer a comprehensive perspective, enabling the assessment of long-term drug safety, medication use patterns, and the associated risks and benefits, particularly utilizing real-world data after drug approval. This research area is critical for exploring adverse reactions and drug interactions specific to cancer treatments and related risk management strategies.
This Research Topic aims to integrate evidence-based medicine into clinical practice to comprehensively address the safety challenges of cancer treatment drugs, optimize therapeutic regimens, reduce the occurrence of ADRs, and ultimately enhance patient outcomes and quality of life.
We welcome submissions on the following topics:
• Real-world evidence of the effectiveness and safety of cancer treatment drugs post-approval.
• Mechanistic studies and strategies for predicting and managing adverse drug reactions.
• Exploration and rational use practices of cancer drugs in clinical settings.
• Perspectives and response strategies of healthcare professionals (physicians, pharmacists, nurses, etc.) regarding adverse reactions to cancer treatment drugs.
• Risk management approaches in pharmacoepidemiology and pharmacovigilance and their applications in cancer treatment.
• Other research related to managing adverse reactions of cancer drugs using pharmacoepidemiological methods and real-world evidence.
Pharmacovigilance is central in this regard, focusing on the detection, evaluation, understanding, and prevention of adverse reactions and other drug-related issues. This discipline includes the early identification of unknown adverse drug reactions and their interactions, monitoring the trends in known reactions, analyzing the risk factors and potential mechanisms, and conducting quantitative risk-benefit assessments. Meanwhile, pharmacoepidemiology applies epidemiological methods and principles to study the use and effects of drugs in specific populations. Through descriptive, analytical (including case-control and cohort studies), and experimental studies (such as randomized controlled trials and community trials), it provides valuable insights and recommendations for rational drug use, thereby making drug development, production, management, and utilization more rational.
Insights gained from pharmacovigilance and pharmacoepidemiology offer a comprehensive perspective, enabling the assessment of long-term drug safety, medication use patterns, and the associated risks and benefits, particularly utilizing real-world data after drug approval. This research area is critical for exploring adverse reactions and drug interactions specific to cancer treatments and related risk management strategies.
This Research Topic aims to integrate evidence-based medicine into clinical practice to comprehensively address the safety challenges of cancer treatment drugs, optimize therapeutic regimens, reduce the occurrence of ADRs, and ultimately enhance patient outcomes and quality of life.
We welcome submissions on the following topics:
• Real-world evidence of the effectiveness and safety of cancer treatment drugs post-approval.
• Mechanistic studies and strategies for predicting and managing adverse drug reactions.
• Exploration and rational use practices of cancer drugs in clinical settings.
• Perspectives and response strategies of healthcare professionals (physicians, pharmacists, nurses, etc.) regarding adverse reactions to cancer treatment drugs.
• Risk management approaches in pharmacoepidemiology and pharmacovigilance and their applications in cancer treatment.
• Other research related to managing adverse reactions of cancer drugs using pharmacoepidemiological methods and real-world evidence.
Keywords: Pharmacovigilance; Pharmacoepidemiology; Adverse Drug Reactions; Cancer Pharmacotherapy.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
